Related Experiment Video
Updated: Jun 5, 2026
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
Published on: June 22, 2020
Slow cardiac myosin regulatory light chain 2 (MYL2) was down-expressed in chronic heart failure patients
Yuanhong Li1, Gang Wu, Qizhu Tang
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Insights
Cardiac myosin light chain 2 (MYL2) protein levels decrease in heart failure (HF) patients. This reduced MYL2 expression correlates with HF severity, suggesting its role in heart failure progression.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Heart Failure Pathophysiology
Background:
- Genetic studies link MYL2 gene mutations to hypertrophic cardiomyopathy, a common cause of heart failure (HF).
- Previous research indicated altered myosin heavy chain expression in HF, prompting investigation into regulatory components like MYL2.
- No direct pathological evidence existed linking MYL2 to HF development prior to this study.
Discussion:
- The study investigated MYL2 protein expression in human heart tissue from chronic HF patients and healthy controls.
- Immunohistochemistry and Western blot analyses quantified MYL2 levels, revealing significant downregulation in HF.
- MYL2 expression was inversely correlated with HF severity (NYHA class), with lower levels in severe cases.
Key Insights:
- MYL2 protein expression is significantly reduced in the heart tissue of patients with chronic heart failure.
- Downregulation of MYL2 is more pronounced in severe heart failure cases (NYHA class III/IV).
- These findings provide the first pathological evidence supporting MYL2's involvement in heart failure.
Outlook:
- Further research is warranted to elucidate the precise mechanisms by which MYL2 downregulation contributes to HF.
- Investigating therapeutic strategies targeting MYL2 could offer new avenues for treating heart failure.
- Understanding MYL2's role may lead to novel biomarkers for HF diagnosis and prognosis.
Background:
Genetic studies have shown that many slow cardiac myosin regulatory light chain 2 (MYL2) gene mutations can cause hypertrophic cardiomyopathy, which is one of the most common causes of heart failure (HF). But until now there has been no pathological or histological evidence that MYL2 may be associated with HF development. Recent microarray studies indicated that myosin heavy chain expression changed in the pathological process of HF. Because MYL2 is a regulatory component of myosin heavy polypeptide, the role of MYL2 protein in HF needs to be studied.
Hypothesis:
The level of expression of MYL2 may change in the heart tissue of patients with chronic HF.
Methods:
We collected 28 human right auricle samples, 16 from chronic HF patients and 12 from healthy control subjects. Immunohistochemistry was carried out to observe the tissue-expression pattern of the MYL2 protein and Western blot methods were performed to quantify the relative MYL2 expression level.
Results:
In chronic HF patients, the MYL2 protein level decreased significantly compared with normal controls (t test P < 0.05). Among the 16 HF patients, MYL2 expression in the severe HF group (New York Heart Association [NYHA] class III or IV) was even lower than that of the moderate HF group (NYHA class II) (t test P < 0.05).
Conclusions:
MYL2 was down-expressed in HF tissues, and our findings suggested that MYL2 may play a role in the development and progression of chronic HF.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:17Pathophysiology of Heart Failure
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...